Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, P.R. China.
Department of Rheumatology and Immunology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110022, P.R. China.
Sci Rep. 2017 Nov 13;7(1):15387. doi: 10.1038/s41598-017-15673-2.
The relationship of platelet-to-lymphocyte ratio (PLR) and survival in urological cancers remained inconsistent in previous studies. Therefore, we performed a meta-analysis to assess the prognostic significance of PLR in patients with urological cancers. A literature search was performed in the PubMed, Embase, and Web of Science up to July, 2017 and study quality was obtained using the Newcastle-Ottawa Scale. To estimate the association of PLR and overall survival (OS) and other survival outcomes in urological cancers, we used pooled hazard ratios (HRs). Subgroup analyses were conducted on different ethnics, sample sizes and cut-off values. 20 high quality studies involving 7562 patients with urological cancers were included in this meta-analysis. High pretreatment PLR was significantly associated with poor OS in patients with urological cancers (pooled HR = 1.58). Elevated PLR was also correlated with other survival outcomes. However, we found that PLR was significantly relevant to the OS of patients with different types of urological cancers except bladder cancer (BCa, HR = 1.16, 95%CI: 0.96-1.41). In conclusion, elevated PLR was negatively related to the OS of patients with urological cancers, except in BCa. However, more large scale prospective studies with high quality are required in the future.
血小板与淋巴细胞比值（PLR）与泌尿系统癌症患者的生存关系在之前的研究中尚不一致。因此，我们进行了荟萃分析，以评估 PLR 在泌尿系统癌症患者中的预后意义。我们在 PubMed、Embase 和 Web of Science 上进行了文献检索，检索时间截至 2017 年 7 月，并使用 Newcastle-Ottawa 量表获得了研究质量。为了评估 PLR 与泌尿系统癌症患者的总生存（OS）和其他生存结局的相关性，我们使用了合并的危险比（HRs）。我们进行了亚组分析，以评估不同的种族、样本量和截止值。本荟萃分析纳入了 20 项高质量的研究，共纳入了 7562 例泌尿系统癌症患者。高术前 PLR 与泌尿系统癌症患者的 OS 不良显著相关（合并 HR=1.58）。升高的 PLR 也与其他生存结局相关。然而，我们发现 PLR 与除膀胱癌（BCa）以外的不同类型泌尿系统癌症患者的 OS 显著相关（HR=1.16，95%CI：0.96-1.41）。总之，升高的 PLR 与泌尿系统癌症患者的 OS 呈负相关，除了 BCa 之外。然而，未来还需要更多高质量的大规模前瞻性研究。
